|
"There is not a shred of information of which causally links Monster to these adverse events and the ... lawsuit is the first the company has ever received," CEO Rodney Sacks told investors during its most recent quarterly earnings call. Monster's stock has lost more than 40 percent of its value since this summer. The company declined to comment Thursday. Morningstar analyst Tom Mullarkey says the recent market decline is overblown. The analyst said that company has made it clear that it believes its products are safe and the FDA has not found that the products are tied to any deaths. Mullarkey also said that Monster's drinks remain popular. While consumers may take pause temporarily when they hear such news, they continue to buy the drink. "I think Monster's long-term growth prospects are still intact," Mullarkey said Thursday. Monster's stock closed the day up 7 cents at $44.81. It dipped about 1 percent in after-hours trading to $44.30.
[Associated
Press;
Copyright 2012 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor